Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Head and Neck Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 108 articles: HTML format

Single Articles

March 2026
1. YANG Y, Yan X, Jiang H, Kang M, et al
   PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.
   Clin Cancer Res. 2026 Mar 2. doi: 10.1158/1078-0432.CCR-25-2367.
   PubMed     Abstract available
   
   
   February 2026
2. YIN S, Cheng L, Hu E, Li J, et al
   Association of Intratumoral Microbiota with Prognosis in Head and Neck Squamous Cell Carcinoma.
   Clin Cancer Res. 2026 Feb 27. doi: 10.1158/1078-0432.CCR-25-4420.
   PubMed     Abstract available
   
   
   
3. MIERZWA M, Rosen B, Suresh K, Dinesh A, et al
   FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
   Clin Cancer Res. 2026;32:684-693.
   PubMed     Abstract available
   
   
   
4. LI JZ, Ricarte Filho J, Isaza AR, Hinkle K, et al
   DNA Methylation-based Risk Stratification and Classification of Pediatric Thyroid Carcinoma.
   Clin Cancer Res. 2026 Feb 17. doi: 10.1158/1078-0432.CCR-25-2109.
   PubMed     Abstract available
   
   
   
5. MICHAL M, Malik F, Mansour B, Hattery T, et al
   FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors.
   Clin Cancer Res. 2026;32:628-644.
   PubMed     Abstract available
   
   
   January 2026
6. PRASAD M, Cheng AT, Mayer M, Jansen L, et al
   Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer.
   Clin Cancer Res. 2026 Jan 28. doi: 10.1158/1078-0432.CCR-25-3972.
   PubMed     Abstract available
   
   
   
7. LEE KW, Bai LY, Jung M, Ying J, et al
   Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.
   Clin Cancer Res. 2026;32:312-323.
   PubMed     Abstract available
   
   
   
8. LI Q, Fu M, Kuang D, Pan C, et al
   A Phase II Trial of Neoadjuvant Albumin-Bound Paclitaxel plus Carboplatin Combined with Tislelizumab in Locally Advanced HNSCC: Efficacy and Biomarker Exploration.
   Clin Cancer Res. 2026;32:324-332.
   PubMed     Abstract available
   
   
   
9. HANNA GJ, Scarfo N, Shin KY, O'Neill A, et al
   Elraglusib, a Glycogen Synthase Kinase 3beta Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma.
   Clin Cancer Res. 2026;32:83-93.
   PubMed     Abstract available
   
   
   December 2025
10. RISCHIN D, Hansen AR, Cohen EEW, Tahara M, et al
    INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-1197.
    PubMed     Abstract available
    
    
    
11. SANZ-GARCIA E, Soleimani S, Bruce JP, Pedersen S, et al
    Investigating Early Kinetics in Plasma ctDNA and Peripheral T Cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Cancer.
    Clin Cancer Res. 2025 Dec 19. doi: 10.1158/1078-0432.CCR-25-3541.
    PubMed     Abstract available
    
    
    
12. LLERENA P, Samarah H, Nunes K, Lin Z, et al
    Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC.
    Clin Cancer Res. 2025;31:5159-5177.
    PubMed     Abstract available
    
    
    
13. ZINNER RG, Mastrolonardo EV, Johnson JM, Nunes K, et al
    Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.
    Clin Cancer Res. 2025 Dec 12. doi: 10.1158/1078-0432.CCR-25-2807.
    PubMed     Abstract available
    
    
    
14. SUN D, Chen G, Chen Y, Qu S, et al
    Anti-LAG-3 Antibody LBL-007 Plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial.
    Clin Cancer Res. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2054.
    PubMed     Abstract available
    
    
    November 2025
15. LI S, Xia S, Lawas M, Kulshreshtha A, et al
    HPV integration in head and neck cancer: downstream splicing events and expression ratios linked with poor outcomes.
    Clin Cancer Res. 2025 Nov 21. doi: 10.1158/1078-0432.CCR-25-0645.
    PubMed     Abstract available
    
    
    
16. KORNS J, Lehn MA, Shyamsunder S, Medvedovic M, et al
    Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer.
    Clin Cancer Res. 2025 Nov 18. doi: 10.1158/1078-0432.CCR-25-2179.
    PubMed     Abstract available
    
    
    
17. LAZARE S, Gu Z, Earland N, Harmon MA, et al
    Postoperative Lymph is a Proximal Source of ctDNA for Detection of Recurrence in HPV-independent Head and Neck Cancer.
    Clin Cancer Res. 2025 Nov 3. doi: 10.1158/1078-0432.CCR-25-1221.
    PubMed     Abstract available
    
    
    October 2025
18. CHAUDHARY R, Moorhead G, Park R, Li J, et al
    Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.
    Clin Cancer Res. 2025 Oct 21. doi: 10.1158/1078-0432.CCR-25-2201.
    PubMed     Abstract available
    
    
    September 2025
19. SEHGAL K
    Personalized Thyroidology: Molecular Rewiring of Thyroid Nodule Management.
    Clin Cancer Res. 2025 Sep 26. doi: 10.1158/1078-0432.CCR-25-2474.
    PubMed     Abstract available
    
    
    August 2025
20. HARING CT, Windon MJ, Heft-Neal ME, Brenner JC, et al
    Toward a Next-Generation Liquid Biopsy for HPV+ HNSCC: Opportunities, Challenges, and the Road Ahead.
    Clin Cancer Res. 2025;31:3359-3361.
    PubMed     Abstract available
    
    
    
21. HONORE N, Laliotis G, Aushev VN, Velichko S, et al
    Tumor-informed ctDNA assay to predict outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with PD-1 inhibitor.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-1309.
    PubMed     Abstract available
    
    
    
22. ROSENBERG AJ, Izumchenko E, Juloori A, Katipally R, et al
    Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer.
    Clin Cancer Res. 2025;31:3150-3159.
    PubMed     Abstract available
    
    
    
23. FU ZM, Bao YY, Dai LB, Zhong JT, et al
    Comprehensive Single-Cell RNA Atlas of Human Laryngeal Normal, Preneoplastic, and Tumorigenic States.
    Clin Cancer Res. 2025;31:3332-3343.
    PubMed     Abstract available
    
    
    July 2025
24. PATEL R, Saab K, Luo L, Ma Y, et al
    Nrf2 hyperactivation as a driver of radiotherapy resistance and suppressed anti-tumor immunity in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2025 Jul 31. doi: 10.1158/1078-0432.CCR-25-0112.
    PubMed     Abstract available
    
    
    
25. CAO F, Li Y, Fang Q, Lin R, et al
    Cadonilimab (a PD-1/CTLA-4 bispecific antibody) Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase ? Clinical Trial.
    Clin Cancer Res. 2025 Jul 24. doi: 10.1158/1078-0432.CCR-25-1445.
    PubMed     Abstract available
    
    
    June 2025
26. HARRISON C, Blake AK, Su Y, Tang L, et al
    Contribution of Germline Predisposition to Pediatric Thyroid Cancer.
    Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0631.
    PubMed     Abstract available
    
    
    
27. DING M, Wu G, Zhang S, Xie R, et al
    Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population.
    Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0270.
    PubMed     Abstract available
    
    
    
28. SABA NF, Flamand Y, Lin DT, Chung CH, et al
    Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163.
    Clin Cancer Res. 2025;31:2339-2346.
    PubMed     Abstract available
    
    
    
29. TANG LQ, Liu SL, Yang MH, Wang HC, et al
    GFH018 and toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: Results from a phase 1b/2 study.
    Clin Cancer Res. 2025 Jun 13. doi: 10.1158/1078-0432.CCR-25-0085.
    PubMed     Abstract available
    
    
    May 2025
30. DHOLARIA H, Tsetlina V, Simpson SK, Gillies E, et al
    One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2025 May 30. doi: 10.1158/1078-0432.CCR-24-3546.
    PubMed     Abstract available
    
    
    
31. BRYAN ME, Aye L, Das D, Hirayama S, et al
    Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers.
    Clin Cancer Res. 2025 May 20:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-2525.
    PubMed     Abstract available
    
    
    
32. SIM ES, Rhoades J, Xiong K, Walsh L, et al
    Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer.
    Clin Cancer Res. 2025 May 20:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0307.
    PubMed     Abstract available
    
    
    
33. CAO X, Luo ZY, Huang HY, Zhou JY, et al
    Capecitabine maintenance therapy in patients with residual nasopharyngeal carcinoma: a single-arm, phase 2 trial.
    Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-24-4132.
    PubMed     Abstract available
    
    
    
34. ALSINA M, Villacampa G, de Andrea C, Vivancos A, et al
    Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
    Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-25-0369.
    PubMed     Abstract available
    
    
    
35. ZHANG W, Li JB, Liu HM, Wang KM, et al
    PERK+ Macrophages Drive Immunotherapy Resistance in Lymph Node Metastases of Oral Squamous Cell Carcinoma.
    Clin Cancer Res. 2025;31:1894-1911.
    PubMed     Abstract available
    
    
    
36. SCHMITT NC, Stokes WA, Bates JE, Kinney BLC, et al
    Early-phase trial of IAP antagonist tolinapant and definitive radiation in cisplatin-ineligible patients with advanced head and neck cancer.
    Clin Cancer Res. 2025 May 12. doi: 10.1158/1078-0432.CCR-25-0429.
    PubMed     Abstract available
    
    
    
37. CALIFANO JA
    So Close, and Yet... Plasma HPV DNA Detection of Recurrent HPV Oropharynx Cancer.
    Clin Cancer Res. 2025;31:1561-1562.
    PubMed     Abstract available
    
    
    
38. QIAN Y, Tang L, Yao J, Zhu Y, et al
    Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study.
    Clin Cancer Res. 2025;31:1636-1643.
    PubMed     Abstract available
    
    
    
39. BARTEMES KR, Moore RM, Novotny BC, Pavelko KD, et al
    Increased Interaction between B Cells and CD3+ T Cells in Nonprogressors with Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2025;31:1719-1729.
    PubMed     Abstract available
    
    
    
40. RETTIG EM, Schoenfeld JD, Miller J, Sargent B, et al
    A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA.
    Clin Cancer Res. 2025;31:1605-1614.
    PubMed     Abstract available
    
    
    
41. GUAN L, Torres-Saavedra PA, Zhao X, Major MB, et al
    Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
    Clin Cancer Res. 2025;31:1615-1624.
    PubMed     Abstract available
    
    
    
42. PEREZ-PACHECO CG, Gonzalez-Maldonado LA, Furgal A, Schmitd LB, et al
    Nerve Types and Classification of Neurons Innervating Oral Cancer.
    Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-24-2375.
    PubMed     Abstract available
    
    
    April 2025
43. FAYETTE J, Licitra L, Harrington K, Haddad R, et al
    INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-25-0073.
    PubMed     Abstract available
    
    
    
44. WALCH HS, Borpatragohain R, Jee J, Chatila W, et al
    Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.
    Clin Cancer Res. 2025 Apr 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-3473.
    PubMed     Abstract available
    
    
    March 2025
45. MCCOON P, Wang Y, Lai Z, Zhang Q, et al
    Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcome.
    Clin Cancer Res. 2025 Mar 13. doi: 10.1158/1078-0432.CCR-24-2198.
    PubMed     Abstract available
    
    
    
46. LEE J, Shin Y, Kwak J, Park HL, et al
    Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer.
    Clin Cancer Res. 2025 Mar 12. doi: 10.1158/1078-0432.CCR-24-3562.
    PubMed     Abstract available
    
    
    
47. TSENG I, Chen Y, Ai D, Zhu Z, et al
    Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Impacted T-Cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy.
    Clin Cancer Res. 2025 Mar 7. doi: 10.1158/1078-0432.CCR-24-4123.
    PubMed     Abstract available
    
    
    
48. COLEVAS AD, Talebi Z, Winters E, Even C, et al
    First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies.
    Clin Cancer Res. 2025;31:815-823.
    PubMed     Abstract available
    
    
    February 2025
49. RAO YJ
    Biomarkers of radioresistance in head and neck cancer: a new beginning.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-4223.
    PubMed     Abstract available
    
    
    
50. WANG C, Niu X, Xia T, Wang P, et al
    Predicting c-KIT Inhibitor Efficacy in Patient-Derived Models of Sinonasal Mucosal Melanomas through Integrated Histogram Analysis of Whole-Tumor DKI, IVIM, and DCE-MRI.
    Clin Cancer Res. 2025 Feb 12. doi: 10.1158/1078-0432.CCR-24-3765.
    PubMed     Abstract available
    
    
    January 2025
51. CONTRERA KJ, Ferrarotto R, Gunn B, Su SY, et al
    Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma.
    Clin Cancer Res. 2025;31:258-265.
    PubMed     Abstract available
    
    
    
52. HUANG YJ, Rieder J, Tan KV, Tenditnaya A, et al
    Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett's Esophagus Using EMI-137 Fluorescence Imaging.
    Clin Cancer Res. 2025;31:98-109.
    PubMed     Abstract available
    
    
    
53. FENGER CARLANDER AL, Jakobsen KK, Todsen T, Paaske N, et al
    Long-term effect and safety of mesenchymal stromal cell therapy for radiation-induced hyposalivation in head and neck cancer survivors: A randomised, phase-2, trial.
    Clin Cancer Res. 2025 Jan 3. doi: 10.1158/1078-0432.CCR-24-2663.
    PubMed     Abstract available
    
    
    December 2024
54. MASON RP
    Tumor Hypoxia: Long Ignored but Now Detectable and Potentially Actionable.
    Clin Cancer Res. 2024;30:5503-5504.
    PubMed     Abstract available
    
    
    
55. DUBEC MJ, Price J, Berks M, Gaffney J, et al
    Oxygen-Enhanced MRI Detects Incidence, Onset, and Heterogeneity of Radiation-Induced Hypoxia Modification in HPV-Associated Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:5620-5629.
    PubMed     Abstract available
    
    
    
56. MICHEL L, Jimeno A, Sukari A, Beck JT, et al
    Sacituzumab Govitecan in Patients With Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results From the Phase 2 TROPiCS-03 Basket Study.
    Clin Cancer Res. 2024 Dec 12. doi: 10.1158/1078-0432.CCR-24-2523.
    PubMed     Abstract available
    
    
    
57. HANNA GJ, Oakley LB, Shi R, ONeill A, et al
    Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-2262.
    PubMed     Abstract available
    
    
    November 2024
58. JOHNSON FM, O'Hara MP, Yapindi L, Jiang P, et al
    Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2290.
    PubMed     Abstract available
    
    
    
59. MASTROLONARDO EV, Nunes KL, Llerena P, Nikitina A, et al
    Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-0037.
    PubMed     Abstract available
    
    
    
60. WANG X, Kang X, Zhang R, Xue L, et al
    Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.
    Clin Cancer Res. 2024;30:5061-5072.
    PubMed     Abstract available
    
    
    
61. LI Q, Zhang W, Liao T, Gao Y, et al
    An AI-driven preoperative radiomic subtype for predicting the prognosis and treatment response of patients with papillary thyroid carcinoma.
    Clin Cancer Res. 2024 Nov 13. doi: 10.1158/1078-0432.CCR-24-2356.
    PubMed     Abstract available
    
    
    October 2024
62. HANSEN AR, Gomez-Roca CA, Robbrecht DGJ, Verlingue L, et al
    Phase 1b Study of the Immunocytokine Simlukafusp alfa (FAP-IL2v), in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-1562.
    PubMed     Abstract available
    
    
    
63. CHAMSEDDINE I, Shah K, Lee H, Ehret F, et al
    Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.
    Clin Cancer Res. 2024;30:4424-4433.
    PubMed     Abstract available
    
    
    September 2024
64. BARRETT AM, Britton ZT, Carrasco RA, Breen S, et al
    Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-24-1853.
    PubMed     Abstract available
    
    
    
65. STONE LD, Kasten BB, Rao S, Gonzalez ML, et al
    Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:4016-4028.
    PubMed     Abstract available
    
    
    
66. WARNER BE, Patel J, Wang R, Adams-Haduch J, et al
    The Epstein-Barr virus nuclear antigen 1 variant associated with nasopharyngeal carcinoma defines the sequence criteria for serologic risk prediction.
    Clin Cancer Res. 2024 Sep 12. doi: 10.1158/1078-0432.CCR-24-1142.
    PubMed     Abstract available
    
    
    August 2024
67. SABA NF, Chaudhary R, Kirtane K, Marra A, et al
    Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis.
    Clin Cancer Res. 2024 Aug 21. doi: 10.1158/1078-0432.CCR-24-1202.
    PubMed     Abstract available
    
    
    
68. HONMA Y, Monden N, Yamazaki K, Kano S, et al
    Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.
    Clin Cancer Res. 2024;30:3416-3427.
    PubMed     Abstract available
    
    
    July 2024
69. FORSTER M, Brana I, Lopez Pousa A, Doger B, et al
    Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0473.
    PubMed     Abstract available
    
    
    June 2024
70. FRENCH JD, Haugen BR, Worden FP, Bowles DW, et al
    Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417.
    PubMed     Abstract available
    
    
    
71. HANNA GJ, Dennis MJ, Scarfo N, Mullin MS, et al
    Personalized circulating tumor DNA for monitoring disease status in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Jun 2. doi: 10.1158/1078-0432.CCR-24-0590.
    PubMed     Abstract available
    
    
    May 2024
72. SCHMIDT I, Zhao X, van der Waaij AM, Meersma GJ, et al
    Ultrasound-guided quantitative fluorescence molecular endoscopy for monitoring response in patients with esophageal cancer following neoadjuvant chemoradiotherapy.
    Clin Cancer Res. 2024 May 30. doi: 10.1158/1078-0432.CCR-24-0446.
    PubMed     Abstract available
    
    
    
73. BALLOUT F, Lu H, Bhat N, Chen L, et al
    Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
    Clin Cancer Res. 2024;30:2193-2205.
    PubMed     Abstract available
    
    
    
74. HANNA GJ, Grover P, Elliott A, McGrath J, et al
    Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Clin Cancer Res. 2024;30:2225-2232.
    PubMed     Abstract available
    
    
    
75. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    PubMed     Abstract available
    
    
    
76. TANG T, Zhou Z, Chen M, Li N, et al
    Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.
    Clin Cancer Res. 2024 May 7. doi: 10.1158/1078-0432.CCR-23-3608.
    PubMed     Abstract available
    
    
    
77. PRENEN H, Deva S, Keam B, Lindsay CR, et al
    Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
    Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677.
    PubMed     Abstract available
    
    
    
78. ROSS RB, Gadwa J, Yu J, Darragh LB, et al
    PPARalpha Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction.
    Clin Cancer Res. 2024;30:1916-1933.
    PubMed     Abstract available
    
    
    
79. LIU Y, Yan W, Hu C, Huang X, et al
    Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance.
    Clin Cancer Res. 2024;30:1801-1810.
    PubMed     Abstract available
    
    
    April 2024
80. SHANNON NB, Iyer NG
    Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions.
    Clin Cancer Res. 2024;30:1223-1225.
    PubMed     Abstract available
    
    
    
81. EARLAND N, Semenkovich NP, Ramirez RJ, Gerndt SP, et al
    Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:1409-1421.
    PubMed     Abstract available
    
    
    
82. READ ML, Brookes K, Zha L, Manivannan S, et al
    Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
    Clin Cancer Res. 2024;30:1352-1366.
    PubMed     Abstract available
    
    
    March 2024
83. ZANONI DK, Demetrio De Souza Franca P, Valero C, Peterson G, et al
    A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer.
    Clin Cancer Res. 2024 Mar 25. doi: 10.1158/1078-0432.CCR-23-1361.
    PubMed     Abstract available
    
    
    
84. SWIECICKI PL, Bellile E, Dragovic AF, McHugh J, et al
    Upfront neck dissection for treatment selection and improvement in quality of life as a novel treatment paradigm for deintensification in HPV+ OPSCC.
    Clin Cancer Res. 2024 Mar 22. doi: 10.1158/1078-0432.CCR-23-3247.
    PubMed     Abstract available
    
    
    
85. KIM CG, Hong MH, Kim D, Lee BH, et al
    A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3249.
    PubMed     Abstract available
    
    
    
86. JAKOBSEN K, Carlander AF, Todsen T, Melchiors J, et al
    Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase 2 Randomised, Placebo-Controlled Trial.
    Clin Cancer Res. 2024 Mar 5. doi: 10.1158/1078-0432.CCR-23-3675.
    PubMed     Abstract available
    
    
    February 2024
87. SAITO S, Kono M, Nguyen HCB, Egloff AM, et al
    Targeting Dendritic Cell Dysfunction to Circumvent anti-PD1 Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2024 Feb 19. doi: 10.1158/1078-0432.CCR-23-3477.
    PubMed     Abstract available
    
    
    January 2024
88. MEHANNA H, Rapozo D, von Zeidler SV, Harrington KJ, et al
    Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study.
    Clin Cancer Res. 2024;30:356-367.
    PubMed     Abstract available
    
    
    
89. LECHNER MG, Brent GA
    A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
    PubMed     Abstract available
    
    
    
90. VON WITZLEBEN A, Ellis M, Thomas GJ, Hoffmann TK, et al
    Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease.
    Clin Cancer Res. 2024;30:224-234.
    PubMed     Abstract available
    
    
    
91. PENA-OYARZUN D, Flores T, Torres VA, Quest AFG, et al
    Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis.
    Clin Cancer Res. 2024;30:209-223.
    PubMed     Abstract available
    
    
    December 2023
92. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    PubMed     Abstract available
    
    
    November 2023
93. NGAMPHAIBOON N, Pattaranutaporn P, Lukerak S, Siripoon T, et al
    A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-2303.
    PubMed     Abstract available
    
    
    
94. OU X, Zhai R, Wei W, Chen J, et al
    Induction Toripalimab And Chemotherapy For Organ Preservation In Locally Advanced Laryngeal And Hypopharyngeal Cancer: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2023 Nov 13. doi: 10.1158/1078-0432.CCR-23-2398.
    PubMed     Abstract available
    
    
    
95. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    PubMed     Abstract available
    
    
    October 2023
96. HANNA GJ, Roof SA, Jabalee J, Rettig EM, et al
    Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.
    Clin Cancer Res. 2023;29:4306-4313.
    PubMed     Abstract available
    
    
    
97. BEYAERT SP, Loriot AE, Huyghe ND, Goebbels RM, et al
    Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111-24111).
    Clin Cancer Res. 2023;29:4076-4087.
    PubMed     Abstract available
    
    
    
98. PIFER PM, Yang L, Kumar M, Xie T, et al
    FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
    Clin Cancer Res. 2023 Oct 11. doi: 10.1158/1078-0432.CCR-23-0964.
    PubMed     Abstract available
    
    
    
99. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    PubMed     Abstract available
    
    
    
100. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
     ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
     Clin Cancer Res. 2023;29:3882-3891.
     PubMed     Abstract available
     
     
     
101. JAKOBSEN KK, Bendtsen SK, Pallisgaard N, Friborg J, et al
     Liquid Biopsies with Circulating Plasma HPV-DNA Measurements-A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer.
     Clin Cancer Res. 2023;29:3914-3923.
     PubMed     Abstract available
     
     
     September 2023
102. DERRY JMJ, Burns C, Frazier JP, Beirne E, et al
     Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment.
     Clin Cancer Res. 2023;29:3813-3825.
     PubMed     Abstract available
     
     
     
103. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
     FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
     Clin Cancer Res. 2023;29:3573-3578.
     PubMed     Abstract available
     
     
     
104. LEE MS, Kaseb AO, Pant S
     The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
     Clin Cancer Res. 2023;29:3267-3274.
     PubMed     Abstract available
     
     
     August 2023
105. CHI Y, Zheng X, Zhang Y, Shi F, et al
     Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
     Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
     PubMed     Abstract available
     
     
     
106. NIU Z, Sun P, Liu H, Wei P, et al
     Functional Genetic Variants in TGFbeta1 and TGFbetaR1 in miRNA-Binding Sites Predict Outcomes in Patients with HPV-positive Oropharyngeal Squamous Cell Carcinoma.
     Clin Cancer Res. 2023;29:3081-3091.
     PubMed     Abstract available
     
     
     
107. DAI Y, Wang Z, Xia Y, Li J, et al
     Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities.
     Clin Cancer Res. 2023;29:2845-2858.
     PubMed     Abstract available
     
     
     June 2023
108. HU H, Ng TSC, Kang M, Scott E, et al
     Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
     Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum